Gut Microbiota Modulation of Chikungunya Virus Infection and Pathogenesis

基孔肯雅病毒感染和发病机制的肠道微生物群调节

基本信息

  • 批准号:
    10597063
  • 负责人:
  • 金额:
    $ 66.15万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-04-01 至 2026-03-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Chikungunya virus (CHIKV) is a mosquito-transmitted, positive-strand enveloped alphavirus that causes global disease in humans. At present, no antiviral agents or licensed vaccines exist for the treatment or prevention of any alphavirus infections. While age, immune status, and pre-existing chronic illness are associated with increased risk of severe CHIKV infection, the role of acquired factors in disease progression is poorly understood. Our preliminary data suggests that the microbiota regulates CHIKV infection, dissemination, and musculoskeletal inflammation and disease through a previously undefined axis by which signals from gut bacteria and bile acids instruct innate immune cell responses to control CHIKV infection of monocytes in circulation and monocyte migration to affected joint tissues. We hypothesize that specific gut bacteria and their microbial constituents modulate CHIKV pathogenesis by regulating antiviral type I IFN and inflammatory responses in pDCs and monocytes. In the absence of these microbial signals, CHIKV disseminates widely, and arthritis ensues after joint infiltration by immune cells. This proposal combines investigators with expertise in alphavirus pathogenesis and immunity (Diamond) and the study of the gut microbiota in disease (Handley, Stappenbeck, and Fischbach). Using a suite of transgenic mice and microbiome reconstitution experiments paired with detailed virological and immunological analyses, we will address the following key questions: (a) which immune cells coordinate the rapid systemic IFN response following CHIKV infection (e.g., pDCs) (b) what immune cues limit viral infection in circulating immune cells (e.g., monocytes)? (c) how does the gut microbiota regulate pDC IFN production and trafficking of circulating immune cells? and (d) which constituents (e.g., metabolites) of the microbiota regulate antiviral and inflammatory responses? Through these detailed mechanistic studies, we expect to link the microbe-derived constituents of specific commensal bacteria with innate antiviral responses that modulate alphavirus infection, dissemination, joint disease, and possibly transmission. Beyond enhancing our understanding of acquired determinants of alphavirus pathogenesis, the findings of this proposal could inform more generally our understanding of how the gut microbiota shapes innate immune responses to limit infection and pathogenesis of other viruses.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michael S Diamond其他文献

West Nile virus: crossing the blood-brain barrier
西尼罗河病毒:穿越血脑屏障
  • DOI:
    10.1038/nm1204-1294
  • 发表时间:
    2004-12-01
  • 期刊:
  • 影响因子:
    50.000
  • 作者:
    Michael S Diamond;Robyn S Klein
  • 通讯作者:
    Robyn S Klein
MDA5 and autoimmune disease
MDA5 与自身免疫性疾病
  • DOI:
    10.1038/ng.2959
  • 发表时间:
    2014-04-28
  • 期刊:
  • 影响因子:
    29.000
  • 作者:
    Jonathan J Miner;Michael S Diamond
  • 通讯作者:
    Michael S Diamond
Zika virus vaccines and monoclonal antibodies: a priority agenda for research and development
寨卡病毒疫苗和单克隆抗体:研发的优先议程
  • DOI:
    10.1016/s1473-3099(24)00750-3
  • 发表时间:
    2025-07-01
  • 期刊:
  • 影响因子:
    31.000
  • 作者:
    Julia T Ostrowsky;Leah C Katzelnick;Nigel Bourne;Alan D T Barrett;Stephen J Thomas;Michael S Diamond;David W C Beasley;Eva Harris;Annelies Wilder-Smith;Tabitha Leighton;Angela J Mehr;Nicolina M Moua;Angela K Ulrich;Ana Cehovin;Petra C Fay;Josephine P Golding;Kristine A Moore;Michael T Osterholm;Eve M Lackritz;Kristina M Adams Waldorf;Jurai Wongsawat
  • 通讯作者:
    Jurai Wongsawat

Michael S Diamond的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michael S Diamond', 18)}}的其他基金

Development of Viral Vaccines against Sarbecoviruses and Merbecoviruses
Sarbecoviruses和Merbecoviruses病毒疫苗的研制
  • 批准号:
    10420516
  • 财政年份:
    2022
  • 资助金额:
    $ 66.15万
  • 项目类别:
The Development and Evaluation of Pan-Coronavirus Vaccines
泛冠状病毒疫苗的研发与评价
  • 批准号:
    10420511
  • 财政年份:
    2022
  • 资助金额:
    $ 66.15万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10420512
  • 财政年份:
    2022
  • 资助金额:
    $ 66.15万
  • 项目类别:
LDLRAD3 Receptor Interaction with Venezuelan Equine Encephalitis Virus
LDLRAD3 受体与委内瑞拉马脑炎病毒的相互作用
  • 批准号:
    10435558
  • 财政年份:
    2021
  • 资助金额:
    $ 66.15万
  • 项目类别:
Gut Microbiota Modulation of Chikungunya Virus Infection and Pathogenesis
基孔肯雅病毒感染和发病机制的肠道微生物群调节
  • 批准号:
    10379327
  • 财政年份:
    2021
  • 资助金额:
    $ 66.15万
  • 项目类别:
LDLRAD3 Receptor Interaction with Venezuelan Equine Encephalitis Virus
LDLRAD3 受体与委内瑞拉马脑炎病毒的相互作用
  • 批准号:
    10314344
  • 财政年份:
    2021
  • 资助金额:
    $ 66.15万
  • 项目类别:
LDLRAD3 Receptor Interaction with Venezuelan Equine Encephalitis Virus
LDLRAD3 受体与委内瑞拉马脑炎病毒的相互作用
  • 批准号:
    10661719
  • 财政年份:
    2021
  • 资助金额:
    $ 66.15万
  • 项目类别:
Systemic Neurotropic virus infection effects on GI Dysmotility
全身嗜神经病毒感染对胃肠道运动障碍的影响
  • 批准号:
    10190929
  • 财政年份:
    2020
  • 资助金额:
    $ 66.15万
  • 项目类别:
Systemic Neurotropic virus infection effects on GI Dysmotility
全身嗜神经病毒感染对胃肠道运动障碍的影响
  • 批准号:
    10611909
  • 财政年份:
    2020
  • 资助金额:
    $ 66.15万
  • 项目类别:
Systemic Neurotropic virus infection effects on GI Dysmotility
全身嗜神经病毒感染对胃肠道运动障碍的影响
  • 批准号:
    10396586
  • 财政年份:
    2020
  • 资助金额:
    $ 66.15万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 66.15万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 66.15万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 66.15万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 66.15万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 66.15万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 66.15万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 66.15万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 66.15万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 66.15万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 66.15万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了